Core Insights - Ingevity Corporation (NGVT) reported a first-quarter 2025 profit of $20.5 million or 56 cents per share, a significant improvement from a loss of $56 million or $1.54 per share in the same quarter last year [1] - Adjusted earnings for the quarter were 99 cents per share, up from 47 cents a year ago, excluding one-time items [1] Revenue Performance - Revenues decreased by 16.5% year over year to $284 million, primarily due to lower sales in the Industrial Specialties product line and the Advanced Polymer Technologies segment [2] - The Performance Chemicals division generated revenues of $95 million, down approximately 35.4% year over year [2] - Road Technologies' product line sales were $44.3 million, down 3% [2] - Industrial Specialties' product line sales fell 50% to $50.7 million due to repositioning measures aimed at exiting lower-margin markets [2] - Performance Materials unit revenues rose around 1.2% year over year to $146.8 million, driven by volume growth in the Asia Pacific region and China [3] - Advanced Polymer Technologies segment sales decreased by 12.1% to $42.2 million, with EBITDA up 31.6% to $12.5 million due to higher utilization rates [4] Financial Metrics - First-quarter operating cash flow was $25.4 million, with free cash flow of $15.4 million [5] - No share repurchases occurred during the quarter, leaving $353.4 million remaining under the current $500 million authorization [5] - Net leverage improved to 3.3x from 3.6x in the previous quarter [5] 2025 Outlook - NGVT revised its 2025 guidance to account for potential risks from lower expected global auto production, projecting sales between $1.25 billion and $1.40 billion and adjusted EBITDA between $380 million and $415 million [6] Stock Performance - NGVT shares have declined by 26.1% over the past year, compared to a 3.1% decline in the industry [7]

FIRST QUARTER 2025 EARNINGS PRESENTATION May 6, 2025 Use of non-GAAP financial measures: This presentation includes certain non‐GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. Reconciliations of non‐GAAP financial measures to GAAP financial measures are provided within the Appendix to this presentation. Investors are urged to consider carefully the comparable GAAP measures and the reconciliations to those measures provided. The company does not attempt to provid ...